Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wallace Nozile

MOHS-Micrographic Surgery Stockbridge, GA Medical Doctor

NPI 1093101107 CMS profile 4219438

110 Eagles Walk, Stockbridge, GA 30281

Open in the dashboard

General payments

$213,162

430 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wallace Nozile of Stockbridge, GA is reported in the CMS Open Payments database as having received $213,162 across 430 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $177,979 205
2024 General $31,275 105
2023 General $1,133 38
2022 General $1,380 46
2021 General $924 31
2020 General $139 2
2019 General $332 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wallace Nozile
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Wallace Nozile were reported at $177,979. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Wallace Nozile MOHS-Micrographic Surgery median Middle half National median
2019 $332 $316 $106–$785 $163
2020 $139 $162 $68–$412 $114
2021 $924 $243 $87–$654 $132
2022 $1,380 $300 $102–$887 $149
2023 $1,133 $364 $125–$1,010 $160
2024 $31,275 $445 $142–$1,108 $164
2025 $177,979 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $146,461 154 payments
  2. Arcutis Biotherapeutics, Inc. $47,598 50 payments
  3. AbbVie, Inc. $13,312 51 payments
  4. Galderma Laboratories, L.P. $1,288 28 payments
  5. Genzyme Corporation $965 38 payments
  6. Lilly USA, LLC $502 17 payments
  7. Regeneron Healthcare Solutions, Inc. $490 10 payments
  8. UCB, Inc. $393 16 payments
  9. Janssen Scientific Affairs, LLC $291 4 payments
  10. Incyte Corporation $275 9 payments
  11. Other $1,589 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $119,997 34 payments
  2. Travel and Lodging $40,008 61 payments
  3. Food and Beverage $29,566 325 payments
  4. Consulting Fee $23,438 7 payments
  5. Education $154 3 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $146,726 157 payments
  2. Zoryve $47,583 49 payments
  3. RINVOQ $13,035 35 payments
  4. DUPIXENT $1,628 65 payments
  5. NEMLUVIO $439 12 payments
  6. Bimzelx $348 15 payments
  7. TALTZ $343 14 payments
  8. AKLIEF Acne $327 6 payments
  9. ORACEA $323 3 payments
  10. AKLIEF Acne $310 4 payments
  11. Other $3,067 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,208

Median for Dermatology: 534

Drug cost

$399,371

Median for Dermatology: $67,151

Branded share of claims

6.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tremfya Guselkumab Brand 12 $147,569
Dupixent Pen Dupilumab Brand 31 $115,815
Taltz Autoinjector Ixekizumab Brand 15 $101,555
Clobetasol Propionate Generic 251 $9,863
Tacrolimus Generic 42 $9,676
Tretinoin Generic 20 $1,906
Metronidazole Generic 39 $1,861
Clindamycin Phosphate Generic 44 $1,850
Hydrocortisone Generic 178 $1,692
Mometasone Furoate Generic 69 $1,546

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$217,858

Of which drugs: $141

Medicare patients

365

Average age 76

Services billed

2,439

168 women, 197 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 37%
Ischemic heart disease 28%
Chronic kidney disease 28%
Cancer 20%
Atrial fibrillation 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 199 $141

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $29,824
  • Janssen Scientific Affairs, LLC $54
$29,878 12 —
DUPIXENT
  • GENZYME CORPORATION $300
  • Regeneron Healthcare Solutions, Inc. $35
$334 31 —
RINVOQ
  • AbbVie, Inc. $191
$191 — —
Bimzelx
  • UCB, Inc. $143
$143 — —
SKYRIZI
  • AbbVie, Inc. $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

430 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record